Key result
FHND004 inhibits hERG K+ currents with ~15-fold less potency than its precursor AZD9291.
Why the study?
The impacts of the new EGFR inhibitor FHND004 on hERG K+ channels and its molecular mechanisms were not previously investigated.
FHND004 demonstrates less potent hERG channel inhibition compared to its precursor AZD9291 in vitro, suggesting a potentially improved cardiac safety profile, though caution remains warranted.
FHND004 may carry lower QT risk than AZD9291; leaves open confirmation in clinical NSCLC use.
FHND004 is a newly synthesized epidermal growth factor receptor (EGFR) inhibitor for the treatment of non-small cell lung cancer (NSCLC). The aim of present study was to investigate the impacts of FHND004 on Human ether-à-go-go-related gene (hERG) K+ channels and the molecular mechanisms underlying of its action. Whole-cell patch clamp recording was performed on wild type (WT), mutant hERG channels heterologously expressed in HEK 293 cells or IKr endogenously expressed in HL-1 cells, respectively. FHND004 inhibited hERG K+ currents in a concentration-dependent manner with IC50 values of 8.46±0.33μM in HEK293 cells and 7.21±0.45μM in HL-1 cells, respectively. However, the inhibitory potency of FHND004 on hERG channels was significantly less than its precursor AZD9291. FHND004-induced inhibition was state-dependent with a preference within open state, but did not alter other kinetics including activation, inactivation, recovery from inactivation or deactivation. In addition, FHND004 exhibited more potent inhibitory effects onWT/A422T and WT/H562P-hERG, two known long QT syndrome (LQTS) associated KCNH2 mutations, than WT alone. Mutations of the residues at pore regions (F656C, Y652A , S624A and F557L) in hERG channels attenuated block effects of FHND004. Taken together, our results demonstrate the evidence that FHND004 is a less potent hERG blocker than its precursor AZD9291. There is, however, a need for caution in the potential use of FHND004 for treating NSCLC patients, especially in those with other concurrent triggering factors.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2018) studied hERG channel inhibition / Non-small cell lung cancer. FHND004 vs. AZD9291 was evaluated on IC50 for hERG tail current block in HEK293 cells. FHND004 inhibited hERG K+ currents with an IC50 of 8.46 µM in HEK293 cells, demonstrating approximately 15-fold less inhibitory potency than its precursor AZD9291.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: